SGS Life Science Services to Expand Shanghai Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SGS Life Science Services to Expand Shanghai Facility

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 8

SGS Life Science Services announced plans to expand its Shanghai, China, cGMP chemistry and microbiology laboratories to 2000-m2 by Q2 2015 and will offer new services from the facility, including a new biotechnology laboratory for cytotoxicity testing, cell-based assays, plus endotoxin and ELISA testing.

The current 1500-m2 facility provides services for method development and validation, testing of raw materials, APIs and finished products, as well as testing of traditional Chinese medicines.

The expansion program, which is due to commence in August 2014, will also see the introduction of packaging testing, including extractables and leachables; an inductively coupled plasma mass spectrometer, for USP<233> Elemental Impurities, will also be located within the laboratory.

Other new capabilities at the Shanghai site will include a dissolution lab for generic drug stability studies, a mycoplasma lab focused on the biological market, and a highly active compound (HAC) testing laboratory to meet growing market demand. In addition to new office space, a drug compatibility study lab, designed to meet regulatory requirements, will also be introduced.

Source: SGS Life Science Services

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here